Our news journalists obtained a quote from the research from Kanazawa University, "Eleven of the 20 cases were positive. Out of those 11 cases, 3 were positive for antibodies against aminoacyl-tRNA synthetase and 3 had antibodies to anti-melanoma differentiation-associated gene 5 detected using an immunoprecipitation assay and/or a specific enzyme-linked immunosorbent assay. One case had anti-NXP-2 antibodies and 4 cases had anti-transcriptional intermediary factor 1 (TIF1)-alpha/gamma antibodies detected by immunoprecipitation and Western blotting. Two of those 4 cases had antibodies for both TIE1-alpha and TIF1-gamma, and the 2 other cases had antibodies for TIF1-gamma alone. We report the 2 cases with antibodies for TIF1-gamma only, who were young-adult females without an internal malignancy or interstitial pneumonia. Those 2 cases had clinically amyopathic DM."
According to the news editors, the research concluded: "Among DM patients with antibodies against TIF1 family proteins, there seems to be a subgroup of young-adult cases who have clinically amyopathic DM and show good prognosis without malignancy."
For more information on this research see: Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-gamma. European Journal of Dermatology, 2012;22(5):668-671. European Journal of Dermatology can be contacted at: John Libbey Eurotext Ltd, 127 Ave De La Republique, 92120 Montrouge, France.
Our news journalists report that additional information may be obtained by contacting E. Matsuura, Kanazawa University, Grad Sch Med Sci, Dept. of Dermatol, Kanazawa, Ishikawa 9208641, Japan.
Keywords for this news article include: Asia, Antibodies, Japan, Ishikawa, Immunology, Dermatology, Polymyositis, Skin Diseases, Blood Proteins, Dermatomyositis, Immunoglobulins, Muscular Diseases, Musculoskeletal Diseases, Skin and Connective Tissue Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.